We and others have previously demonstrated that delivery of an agonist antibody to OX40 immediately following radiation therapy significantly increased survival in the 3LL lung carcinoma model [5, 18], but it is possible that this timing is also not optimal. The gene discussed is TNFRSF4; the disease is lung carcinoma.